Lipegis

Ezetimibe, the active ingredient in Lipegis, is a cholesterol absorption inhibitor presented as a tablet for oral use. It lowers low‑density lipoprotein cholesterol in adults with primary hypercholesterolemia, heterozygous familial hypercholesterolemia, or mixed hyperlipidemia.

GNH USA supplies Lipegis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed globally.

Lipegis (ezetimibe) is used to manage disorders of lipid metabolism, primarily by reducing elevated cholesterol levels.

- Hypercholesterolemia: lowers LDL‑C and total cholesterol in patients with primary high cholesterol. - Heterozygous familial hypercholesterolemia: provides additional LDL‑C reduction when combined with statins. - Hyperlipidemia: improves overall lipid profile, decreasing triglycerides and non‑HDL cholesterol.

Ezetimibe may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Abdominal pain: mild discomfort in the stomach area. - Diarrhea: loose stools occurring intermittently. - Fatigue: feeling unusually tired. - Headache: mild to moderate head pain. - Nausea: sensation of needing to vomit. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Severe allergic reactions: including angioedema or anaphylaxis. - Hepatitis: inflammation of the liver with jaundice. - Rhabdomyolysis: muscle breakdown, especially when combined with statins. - Pancreatitis: inflammation of the pancreas. - Cholestatic jaundice: impaired bile flow leading to yellowing of skin and eyes.

Before initiating therapy, clinicians should consider several safety aspects.

- Pregnancy: Category B; use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: limited data; weigh maternal benefit against possible infant exposure. - Liver disease: monitor hepatic function tests regularly. - Concomitant statin therapy: assess risk of myopathy and adjust monitoring. - Renal impairment: no dose adjustment required, but monitor overall lipid profile. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ezetimibe can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Cyclosporine: may increase ezetimibe plasma concentrations. - Fibrates combined with statins: heightened risk of myopathy. - Antacids containing aluminum or magnesium: can reduce ezetimibe absorption.

Moderate Interactions (Monitor Closely): - Statins: additive LDL‑C lowering; monitor liver enzymes and muscle symptoms. - Warfarin: possible alteration of INR; check coagulation status regularly. - Bile acid sequestrants: may diminish ezetimibe efficacy; separate dosing by at least 2 hours.